The S&P/TSX Composite index closed 0.5% higher at the 20,881 level on Friday , reaching the highest since May 2022, supported by looser financial conditions. Preliminary data indicated that the Canadian GDP expanded from the previous month in November, while that for October was revised to show a stall. This aligns loosely with the Bank of Canada’s outlook for the...
When HMM.A (TSX) reaches the demand zone between $7.91 and $8.10 and coincides with the closing of the currently forming descending triangle at the drawn demand line, I plan to initiate a buy position. This decision aligns with my strategy to capitalize on potential increased demand and the pattern's breakout. My exit goal for this trade is set between $8.36 and $8.62.
Statement: "Based on the demand and supply zones I've mapped out in my trading analysis, I'm eyeing MR.UN closely. If it enters the demand zone between $3.10 and $3.70, coupled with confirmation of an ascending triangle, I intend to enter a position. This strategy aligns with the potential for increased buying pressure in the demand zone, and the pattern's...
Royal Bank of Canada is sitting in monthly and weekly demand. It is ready for long term bullish run on the upside.
(TSX: HEM) There are several top stem cell companies that are engaged in various activities related to stem cell research, development, and commercialization. The top companies are engaged in the development of regenerative medicine products based on mesenchymal lineage adult stem cells. The top stem cell companies are engaged in various activities related to stem...
The global biotechnology market was estimated to be worth USD 859.94 billion in 2022 and is expected to be worth around USD 1,683.52 billion by 2030, with a notable CAGR of 8.7% from 2023 to 2030. Investors should pay attention to productive small caps in the game, such as $HEM, which has shown immense growth potential in the years to come. Hemostemix, Inc. has...
Hemostemix Inc. (TSXV: HEM) has emerged as a pioneer biotechnology company in the healthcare sector. This company is continuously thriving to shape and develop blood-derived stem cell therapies for medical conditions. With its innovative approach and proficient technology, the company constantly tries to improve the lives of patients with cardiovascular diseases,...
Hemostemix (HEM) is a biotechnology company that develops and commercializes innovative stem cell therapies for medical conditions that are currently underserved by existing treatments. HEM's proprietary technology allows it to isolate and culture a patient's own stem cells, which are then used to treat a variety of conditions, including critical limb ischemia,...
Hemostemix Inc. (TSXV: HEM) has emerged as a pioneer biotechnology company in the healthcare sector. This company is continuously thriving to shape and develop blood-derived stem cell therapies for medical conditions. With its innovative approach and proficient technology, the company constantly tries to improve the lives of patients with cardiovascular diseases,...
I have been actively monitoring the inside bar pattern working on various Canadian stocks, I am just journalising and checking the win ratio for the same before I invest.
$DIA is responsible for seventy percent of all millionaires. This stock has made more money than all other industrial investments combined. Today's wise young person or wage earner invests their money in $DIA.
The company recently announced that DR Alberto Sola, CO-Founder of Universal Ibogaine, will present his recent findings in the title Ibogaine Hydrochloride and Acute Opioid Detox.
The trading just got a green signal on the TSX-V, and $IBO zoomed past the fellow penny stocks in a flicker; what a scene it was; I am amazed and satisfied to buy some shares of it
Let’s go fellow shareholders of $IBO it is the day to be proud of yourself for trusting in $IBO, I am so enlivened to see this stock reaching the heights it was always meant to reach
$IBO is moving ahead with courage and compassion on the TSX-V, the stock is expanding in leaps and bounds in the market, shares are effectively trading at $0.0400 with zero loss percentage
$DIA has marked a rather brilliant opening on the TSX-V and is moving ahead with an unmatched pace and stock trading at suitable buying price of $0.1800 to generate heavy profit
$IBO don’t ever shy out from attaining peaks in the market and delivering unimaginable profit to the shareholders, the shares are trading yesterday with a massive spike of 10% at $0.0500 with sizeable ascent
UI's common shares have been listed for trading on the Frankfurt Stock Exchange, or Bourse Frankfurt, under the ticker symbol "JC4". In Canada, UI will continue to trade on the TSX Venture Exchange under the ticker IBO and on the OTCQB under the ticker symbol IBOGF.